Zhiwei Zheng

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 9

Top Topics

Squamous Cell Carcinoma

Chemotherapy Induced

Small Cell Lung Cancer

Top Venues

Therapeutic advances in medical oncology

Journal of clinical pharmacy and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Zhiwei Zheng, Ling Fang, Hongfu Cai
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis. BMJ open 13 (12) (2023)
Zhiwei Zheng, Ling Fang, Hongfu Cai
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis. BMJ open 13 (12) (2023)
Zhiwei Zheng, Ling Fang, Hongfu Cai
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis. BMJ open 13 (12) (2023)
Zhiwei Zheng, Ling Fang, Hongfu Cai
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis. BMJ open 13 (12) (2023)
Zhiwei Zheng, Ling Fang, Hongfu Cai
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis. BMJ open 13 (12) (2023)
Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng
Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis. Therapeutic advances in medical oncology 15 (2023)
Zhiwei Zheng, Ling Fang, Hongfu Cai, Huide Zhu
Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma. Immunotherapy (2023)
Zhiwei Zheng, Ling Fang, Hongfu Cai
First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis. BMJ open 13 (12) (2023)
Liu Yang, Zhiwei Zheng, Na Li, Bin Zheng, Maobai Liu, Hongfu Cai
Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis. Journal of clinical pharmacy and therapeutics (2022)